{"id":365384,"date":"2026-06-17T16:34:02","date_gmt":"2026-06-17T11:04:02","guid":{"rendered":"https:\/\/forumias.com\/blog\/?p=365384"},"modified":"2026-06-17T16:34:02","modified_gmt":"2026-06-17T11:04:02","slug":"dengiall-vaccine","status":"publish","type":"post","link":"https:\/\/forumias.com\/blog\/dengiall-vaccine\/","title":{"rendered":"DengiAll Vaccine"},"content":{"rendered":"<div class=\"content-box-green\">\n<p><strong>News<\/strong>: Concerns have emerged over DengiAll after severe adverse events during Brazil\u2019s Butantan-DV dengue vaccination campaign.<\/p>\n<\/div>\n<h2 class=\"yellow-h2-box\">About DengiAll Vaccine<\/h2>\n<ul>\n<li><strong>DengiAll<\/strong>: It is <strong>India\u2019s indigenous tetravalent dengue vaccine<\/strong> designed to <strong>protect against all four dengue virus<\/strong> serotypes.<\/li>\n<li><strong>Developed by:<\/strong> DengiAll has been <strong>developed by Panacea Biotec<\/strong> in collaboration with the <strong>Indian Council of Medical Research (ICMR).<\/strong><\/li>\n<li><strong>Vaccine Type:<\/strong> DengiAll is a <strong>live-attenuated tetravalent dengue vaccine<\/strong> that combines weakened forms of DENV-1, DENV-2, DENV-3, and DENV-4.\n<ul>\n<li><strong>Live-Attenuated Vaccines:<\/strong> These <strong>vaccines contain weakened forms of pathogens<\/strong> that can trigger a strong and long-lasting immune response without causing illness in healthy individuals.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Current Status:<\/strong> The <strong>Phase 3 clinical trial of DengiAll was conducted in 2024<\/strong> with more than 10,335 participants across 19 sites in 18 States and Union Territories.<\/li>\n<li><strong>Dosing<\/strong>: DengiAll is a <strong>two-dose vaccine<\/strong> followed by <strong>two years of medical follow-up.<\/strong><\/li>\n<li><strong>Efficiency<\/strong>: Early Phase 1 and Phase 2 clinical trials demonstrated an <strong>efficacy rate of 77% to 82%<\/strong> and showed a <strong>balanced antibody response against all four dengue virus serotypes,<\/strong> indicating promising protection against dengue infection.<\/li>\n<li><strong>NIH-Based Technology<\/strong>: It is <strong>derived from the TV003\/TV005 strain<\/strong> originally <strong>developed by the U.S. National Institutes of Health (NIH).<\/strong><\/li>\n<\/ul>\n<h2>About Dengue<\/h2>\n<ul>\n<li><strong>Nature of Disease:<\/strong> Dengue, also known as <strong>break-bone fever<\/strong>, is a <strong>mosquito-borne viral infection.<\/strong><\/li>\n<li><strong>Occurrence<\/strong>: It is more <strong>common in tropical and subtropical regions,<\/strong> especially in urban and semi-urban areas.<\/li>\n<li><strong>Transmission<\/strong>: The disease spreads through the <strong>bite of infected Aedes mosquitoes<\/strong> carrying one of the four dengue virus serotypes.<\/li>\n<li><strong>Serotypes<\/strong>: The <strong>dengue virus has four serotypes\u2014<\/strong>DENV-1, DENV-2, DENV-3, and DENV-4\u2014and <strong>all four serotypes are known to circulate in India.<\/strong><\/li>\n<li><strong>Symptoms<\/strong>: Common symptoms include high fever, headache, body aches, nausea, and rash, while severe cases may cause bleeding and breathing difficulties.<\/li>\n<li><strong>Treatment<\/strong>: There is no specific medicine for dengue, and treatment mainly involves pain relief, rest, and adequate fluid intake.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>News: Concerns have emerged over DengiAll after severe adverse events during Brazil\u2019s Butantan-DV dengue vaccination campaign. About DengiAll Vaccine DengiAll: It is India\u2019s indigenous tetravalent dengue vaccine designed to protect against all four dengue virus serotypes. Developed by: DengiAll has been developed by Panacea Biotec in collaboration with the Indian Council of Medical Research (ICMR).&hellip; <a class=\"more-link\" href=\"https:\/\/forumias.com\/blog\/dengiall-vaccine\/\">Continue reading <span class=\"screen-reader-text\">DengiAll Vaccine<\/span><\/a><\/p>\n","protected":false},"author":10401,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":""},"categories":[1566,1738,12039],"tags":[11872],"class_list":["post-365384","post","type-post","status-publish","format-standard","hentry","category-daily-factly-articles","category-science-and-technology-daily-factly-articles","category-knolls","tag-9pm-daily-factly","entry"],"jetpack_featured_media_url":"","views":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts\/365384","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/users\/10401"}],"replies":[{"embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/comments?post=365384"}],"version-history":[{"count":0,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts\/365384\/revisions"}],"wp:attachment":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/media?parent=365384"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/categories?post=365384"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/tags?post=365384"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}